Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.42 |
| ▸ | LIPC | P11150 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641375 | 0.83 | HSP90AA1 (0.53) | APEX1CNR1CNR2LMNAHPGD | |
| SCHEMBL1641394 | 0.82 | CNR1 (0.53) | TSHRAPEX1CNR1CNR2LMNA | |
| SCHEMBL1641080 | 0.80 | LMNA (0.47) | APEX1CNR1CNR2LMNASMN1; SMN2 | |
| SCHEMBL1642234 | 0.79 | WDR5 (0.46) | CNR1CNR2LMNAHPGDMEN1 | |
| SCHEMBL1640737 | 0.79 | EGLN3 (0.60) | TSHRAPEX1CNR1CNR2LMNA | |
| SCHEMBL5759410 | 0.77 | PDE10A (0.48) | TSHRAPEX1CNR1CNR2LMNA | |
| SCHEMBL1641018 | 0.75 | CNR1 (0.49) | TSHRAPEX1CNR1CNR2HPGD | |
| SCHEMBL1640291 | 0.75 | CA12 (0.41) | TSHRCNR1CNR2LMNASMN1; SMN2 | |
| SCHEMBL1640561 | 0.74 | HRH3 (0.52) | TSHRAPEX1CNR1CNR2HPGD | |
| SCHEMBL1642162 | 0.74 | LMNA (0.43) | CNR1CNR2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | TSHR 3229/4885APEX1 1143/4885CNR1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.